Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model

Yoko Kita; Takao Tanaka; Shigeto Yoshida; Naoya Ohara; Yasufumi Kaneda; Sachiko Kuwayama; Yumiko Muraki; Noriko Kanamaru; Satomi Hashimoto; Hiroko Takai; Chika Okada; Yukari Fukunaga; Yayoi Sakaguchi; Izumi Furukawa; Kyoko Yamada; Yoshikazu Inoue; Yuji Takemoto; Mariko Naito; Takeshi Yamada; Makoto Matsumoto; David N. McMurray; E. C. Dela Cruz; E. V. Tan; R. M. Abalos; J. A. Burgos; Robert Gelber; Yasir Skeiky; Steven Reed; Mitsunori Sakatani; Masaji Okada

doi:10.1016/j.vaccine.2005.01.057

Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model

Yoko Kita, Takao Tanaka, Shigeto Yoshida, Naoya Ohara, Yasufumi Kaneda, Sachiko Kuwayama, Yumiko Muraki, Noriko Kanamaru, Satomi Hashimoto, Hiroko Takai, Chika Okada, Yukari Fukunaga, Yayoi Sakaguchi, Izumi Furukawa, Kyoko Yamada, Yoshikazu Inoue, Yuji Takemoto, Mariko Naito, Takeshi Yamada, Makoto MatsumotoDavid N. McMurray, E. C. Dela Cruz, E. V. Tan, R. M. Abalos, J. A. Burgos, Robert Gelber, Yasir Skeiky, Steven Reed, Mitsunori Sakatani, Masaji Okada

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

We have developed two novel tuberculosis (TB) vaccines: a DNA vaccine combination expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) by using the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ) and a recombinant BCG harboring the 72f fusion gene (72f rBCG). These vaccines provide remarkable protective efficacy in mouse and guinea pig models, as compared to the current by available BCG vaccine. In the present study, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis, to evaluate the HSP65 + IL-12/HVJ and 72f rBCG vaccines. Vaccination with HSP65 + IL-12/HVJ as well as 72f rBCG vaccines provided better protective efficacy as assessed by the Erythrocyte Sedimentation Rate, chest X-ray findings and immune responses than BCG. Most importantly, HSP65 + IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model.

Original language	English
Pages (from-to)	2132-2135
Number of pages	4
Journal	Vaccine
Volume	23
Issue number	17-18
DOIs	https://doi.org/10.1016/j.vaccine.2005.01.057
Publication status	Published - Mar 18 2005
Externally published	Yes

Keywords

HSP65 DNA + IL-12 DNA vaccine
Monkey
Tuberculosis

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.01.057

Cite this

Kita, Y., Tanaka, T., Yoshida, S., Ohara, N., Kaneda, Y., Kuwayama, S., Muraki, Y., Kanamaru, N., Hashimoto, S., Takai, H., Okada, C., Fukunaga, Y., Sakaguchi, Y., Furukawa, I., Yamada, K., Inoue, Y., Takemoto, Y., Naito, M., Yamada, T., ... Okada, M. (2005). Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine, 23(17-18), 2132-2135. https://doi.org/10.1016/j.vaccine.2005.01.057

Kita, Y, Tanaka, T, Yoshida, S, Ohara, N, Kaneda, Y, Kuwayama, S, Muraki, Y, Kanamaru, N, Hashimoto, S, Takai, H, Okada, C, Fukunaga, Y, Sakaguchi, Y, Furukawa, I, Yamada, K, Inoue, Y, Takemoto, Y, Naito, M, Yamada, T, Matsumoto, M, McMurray, DN, Dela Cruz, EC, Tan, EV, Abalos, RM, Burgos, JA, Gelber, R, Skeiky, Y, Reed, S, Sakatani, M & Okada, M 2005, 'Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model', Vaccine, vol. 23, no. 17-18, pp. 2132-2135. https://doi.org/10.1016/j.vaccine.2005.01.057

@article{b2550e51590741e0bdfa895b5cdbfcd8,

title = "Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model",

abstract = "We have developed two novel tuberculosis (TB) vaccines: a DNA vaccine combination expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) by using the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ) and a recombinant BCG harboring the 72f fusion gene (72f rBCG). These vaccines provide remarkable protective efficacy in mouse and guinea pig models, as compared to the current by available BCG vaccine. In the present study, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis, to evaluate the HSP65 + IL-12/HVJ and 72f rBCG vaccines. Vaccination with HSP65 + IL-12/HVJ as well as 72f rBCG vaccines provided better protective efficacy as assessed by the Erythrocyte Sedimentation Rate, chest X-ray findings and immune responses than BCG. Most importantly, HSP65 + IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model.",

keywords = "HSP65 DNA + IL-12 DNA vaccine, Monkey, Tuberculosis",

author = "Yoko Kita and Takao Tanaka and Shigeto Yoshida and Naoya Ohara and Yasufumi Kaneda and Sachiko Kuwayama and Yumiko Muraki and Noriko Kanamaru and Satomi Hashimoto and Hiroko Takai and Chika Okada and Yukari Fukunaga and Yayoi Sakaguchi and Izumi Furukawa and Kyoko Yamada and Yoshikazu Inoue and Yuji Takemoto and Mariko Naito and Takeshi Yamada and Makoto Matsumoto and McMurray, {David N.} and {Dela Cruz}, {E. C.} and Tan, {E. V.} and Abalos, {R. M.} and Burgos, {J. A.} and Robert Gelber and Yasir Skeiky and Steven Reed and Mitsunori Sakatani and Masaji Okada",

note = "Funding Information: This study was supported by a Health and Labour Science Research Grant from MHLW (H11-shinko-2, H14-shinko-1) and international collaborative study grants from Human Science foundation.",

year = "2005",

month = mar,

day = "18",

doi = "10.1016/j.vaccine.2005.01.057",

language = "English",

volume = "23",

pages = "2132--2135",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "17-18",

}

TY - JOUR

T1 - Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model

AU - Kita, Yoko

AU - Tanaka, Takao

AU - Yoshida, Shigeto

AU - Ohara, Naoya

AU - Kaneda, Yasufumi

AU - Kuwayama, Sachiko

AU - Muraki, Yumiko

AU - Kanamaru, Noriko

AU - Hashimoto, Satomi

AU - Takai, Hiroko

AU - Okada, Chika

AU - Fukunaga, Yukari

AU - Sakaguchi, Yayoi

AU - Furukawa, Izumi

AU - Yamada, Kyoko

AU - Inoue, Yoshikazu

AU - Takemoto, Yuji

AU - Naito, Mariko

AU - Yamada, Takeshi

AU - Matsumoto, Makoto

AU - McMurray, David N.

AU - Dela Cruz, E. C.

AU - Tan, E. V.

AU - Abalos, R. M.

AU - Burgos, J. A.

AU - Gelber, Robert

AU - Skeiky, Yasir

AU - Reed, Steven

AU - Sakatani, Mitsunori

AU - Okada, Masaji

N1 - Funding Information: This study was supported by a Health and Labour Science Research Grant from MHLW (H11-shinko-2, H14-shinko-1) and international collaborative study grants from Human Science foundation.

PY - 2005/3/18

Y1 - 2005/3/18

N2 - We have developed two novel tuberculosis (TB) vaccines: a DNA vaccine combination expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) by using the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ) and a recombinant BCG harboring the 72f fusion gene (72f rBCG). These vaccines provide remarkable protective efficacy in mouse and guinea pig models, as compared to the current by available BCG vaccine. In the present study, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis, to evaluate the HSP65 + IL-12/HVJ and 72f rBCG vaccines. Vaccination with HSP65 + IL-12/HVJ as well as 72f rBCG vaccines provided better protective efficacy as assessed by the Erythrocyte Sedimentation Rate, chest X-ray findings and immune responses than BCG. Most importantly, HSP65 + IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model.

AB - We have developed two novel tuberculosis (TB) vaccines: a DNA vaccine combination expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) by using the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ) and a recombinant BCG harboring the 72f fusion gene (72f rBCG). These vaccines provide remarkable protective efficacy in mouse and guinea pig models, as compared to the current by available BCG vaccine. In the present study, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis, to evaluate the HSP65 + IL-12/HVJ and 72f rBCG vaccines. Vaccination with HSP65 + IL-12/HVJ as well as 72f rBCG vaccines provided better protective efficacy as assessed by the Erythrocyte Sedimentation Rate, chest X-ray findings and immune responses than BCG. Most importantly, HSP65 + IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model.

KW - HSP65 DNA + IL-12 DNA vaccine

KW - Monkey

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=20044385066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044385066&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.01.057

DO - 10.1016/j.vaccine.2005.01.057

M3 - Article

C2 - 15755583

AN - SCOPUS:20044385066

SN - 0264-410X

VL - 23

SP - 2132

EP - 2135

JO - Vaccine

JF - Vaccine

IS - 17-18

ER -

Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this